Evaluating new treatment combinations for newly diagnosed multiple myeloma patients not eligible for transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of combining Elranatamab with Daratumumab and Lenalidomide, or Elranatamab with Lenalidomide, in comparison to the combination of Daratumumab, Lenalidomide, and Dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant. The study is divided into two parts: the first part focuses on assessing the safety and tolerability of these combinations and determining the optimal dosing, while the second part evaluates the effectiveness in achieving minimal residual disease negativity and progression-free survival. The goal is to identify a more effective treatment regimen for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of multiple myeloma (MM) as defined by IMWG criteria (Rajkumar et al., 2014)
* Measurable disease based on IMWG criteria as defined by at least 1 of the following:

  * Serum M-protein ≥0.5 g/dL (Part 1) and ≥1 g/dL (Part 2);
  * Urinary M-protein excretion ≥200 mg/24 hours;
  * Involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65).
* Part 1: Participants with relapsed/refractory multiple myeloma (RRMM) who have received 1-2 prior lines of therapy including at least one immunomodulatory drug and one proteasome inhibitor: or participants with newly-diagnosed multiple myeloma (NDMM) that are transplant-ineligible as defined by age ≥65 years or transplant-ineligible as defined by age \<65 years with comorbidities impacting the possibility of transplant.
* Part 2: participants with newly-diagnosed multiple myeloma that are transplant-ineligible defined as:

  * Participants not considered candidates for high-dose chemotherapy and ASCT due to age or
  * Participants with important comorbidities likely to have a negative impact on tolerability of high dose chemotherapy and ASCT.
* ECOG performance status ≤2.
* Not pregnant and willing to use contraception
* For participants with RRMM: Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

Exclusion Criteria:

* Smoldering Multiple Myeloma.
* Monoclonal gammopathy of undetermined significance.
* Waldenströms Macroglobulinemia
* Plasma cell leukemia.
* Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19/SARS-CoV-2, HBV, HCV, and known HIV or AIDS-related illness.
* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or Stage 0/1 with minimal risk of recurrence per investigator.
* For participants with RRMM: Previous treatment with a BCMA-directed therapy or anti-CD38-directed therapy within 6 months preceding the first dose of study intervention in this study. Stem cell transplant ≤3 months prior to first dose of study intervention or active GVHD.
* For participants with NDMM: Previous systemic treatment for MM except for a short course of corticosteroids (ie, total of 160 mg dexamethasone or equivalent before the first dose of study intervention). A cumulative dose of systemic corticosteroids equivalent to ≥20 mg of dexamethasone during screening.
* Live attenuated vaccine administered within 4 weeks of the first dose of study intervention.
* Administration of investigational product (eg, drug or vaccine) concurrent with study intervention or within 30 days (or as determined by the local requirement) preceding the first dose of study intervention used in this study.

Where it's running

• Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis
  Daphne, Alabama, United States Recruiting
• Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center
  Daphne, Alabama, United States Recruiting
• Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope
  Fairhope, Alabama, United States Recruiting
• Mobile Infirmary Association d/b/a Mobile Infirmary Medical Center
  Mobile, Alabama, United States Recruiting
• Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Mobile
  Mobile, Alabama, United States Recruiting
• Mobile Infirmary Medical Center
  Mobile, Alabama, United States Recruiting

+130 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Elranatamab alone or with daratumumab for people with multiple myeloma after prior treatment

  This trial will test whether the BCMA-targeting drug elranatamab alone or together with daratumumab helps people with multiple myeloma who have already been treated with lenalidomide, compared with daratumumab plus pomalidomide and dexamethasone.

  Recruiting at 80 sites Phase 3 Pfizer · Clovis, California and 236 other locations · NCT05020236

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Maintaining myeloma with less frequent daratumumab plus lenalidomide

  This phase 2 study tests a reduced-dosing schedule of daratumumab with lenalidomide to maintain remission in adults with multiple myeloma after stem cell transplant.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07485647

• Elranatamab plus cyclophosphamide for relapsed/refractory multiple myeloma with high-risk features

  This will test whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that might make elranatamab alone less effective.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07454382

• GR1803 injection versus daratumumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether GR1803 injection works better than daratumumab combined with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have had one to three prior treatments.

  Recruiting Phase 3 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tianjin · NCT07452198

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.